GlaxoSmithKline in Major Reversal on Drugs

In a major change of strategy, the new head of GlaxoSmithKline, Andrew Witty, has told the Guardian he will slash prices on all medicines in the poorest countries, give back profits to be spent on hospitals and clinics and--most ground-breaking of all--share knowledge about potential drugs that are currently protected by patents.